The US Food and Drug Administration said Tuesday it has approved the first drug made with a 3-D printer -- pills for treating epilepsy.
The Ohio-based company Aprecia Pharmaceuticals said its system can produce doses of up to 1,000 mg per tablet.
It said the product is a "porous formulation" that dissolves with just a sip of liquid, making it convenient for people who have trouble swallowing pills or for getting children to take medication.
FDA spokeswoman Sandy Walsh confirmed to AFP that the medication known as Spritam is the first made with a 3-D printer that the agency has approved.
Spritam, or Levetiracetam, has already been on the market for years in other formats, Walsh said.
Aprecia, which is not listed, plans to start distributing the medication in the first quarter of next year.
The FDA had already given the green light to other medical products made with such 3-D technology, such as prosthetic devices.
Aprecia said on its website that in coming years it plans to develop other kinds of medication with the new technology.
The health care industry is turning more and more to 3-D printers to produce custom-made implants for patients with rare pathologies or with certain kinds of injuries.
GMT 10:31 2018 Tuesday ,13 November
Russian police uproot 70 underground drug labs in past six monthsGMT 16:32 2018 Tuesday ,06 November
Rwanda aims to achieve universal access to clean water by 2024GMT 16:57 2018 Sunday ,04 November
Palestinian women witness higher cure rate of breast cancerGMT 13:11 2018 Tuesday ,30 October
Emergency surgery saves life of touristGMT 10:44 2018 Tuesday ,23 October
Scientists find microplastics in human stool for first timeGMT 09:18 2018 Tuesday ,23 October
US judge upholds Monsanto weedkiller cancer verdict, reduces payoutGMT 14:22 2018 Friday ,19 October
Birth spacing ‘improving health of Omani women’GMT 15:40 2018 Monday ,15 October
Pakistani president launches nationwide anti-measles driveMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor